MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

MDT

98.64

+1.99%↑

135.65

-2.83%↓

VEEV

215.94

-2.8%↓

HQY

83.67

-1.59%↓

NEOG

9.34

+1.19%↑

Home・Akciju saraksts・NeoGenomics Inc

NeoGenomics Inc

Slēgts

12.63 -1.1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.24

Max

12.77

Galvenie mērījumi
By Trading Economics
Ienākumi	18M -27M
Pārdošana	6.5M 188M
Peļņas marža	-14.446
Darbinieki	2,200
EBITDA	38M -10M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+9.46% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 17. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	304M 1.6B
Iepriekšējā atvēršanas cena	13.73
Iepriekšējā slēgšanas cena	12.63

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

7.7 / 10.27 Atbalsts un pretestība

NeoGenomics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 16. janv. 16:01 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

Riot Platforms Shares Rise After Texas Land Buy, Data Center Lease

2026. g. 15. janv. 17:51 UTC

Galvenie tirgus virzītāji

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

2026. g. 6. janv. 17:41 UTC

Galvenie tirgus virzītāji

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

2026. g. 20. janv. 13:42 UTC

Tirgus saruna

Cryptocurrencies Fall as Risk Aversion Drives Global Stocks Lower -- Market Talk

2026. g. 20. janv. 11:53 UTC

Peļņas

U.S. Bancorp Says It Has Completed Pilot to Enable Cross-Border Stablecoin Transactions >USB

2026. g. 20. janv. 08:13 UTC

Tirgus saruna

Bitcoin, Ether Fall on Risk Aversion Over U.S.-Europe Tensions -- Market Talk

2026. g. 19. janv. 13:29 UTC

Tirgus saruna

Recovery in Bitcoin, Ether Stall Amid U.S.-Europe Tensions -- Market Talk

2026. g. 19. janv. 07:15 UTC

Tirgus saruna

Cryptocurrencies Fall Amid Risk-Off Sentiment -- Market Talk

2026. g. 16. janv. 13:35 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 16. janv. 13:35 UTC

Tirgus saruna

Demand For Potential Digital Euro Will Determine Its Impact -- Market Talk

2026. g. 16. janv. 08:08 UTC

Tirgus saruna

Bitcoin Falls as Traders Take Profits -- Market Talk

2026. g. 15. janv. 08:23 UTC

Tirgus saruna

Bitcoin Eases Following Falls in Tech Stocks -- Market Talk

2026. g. 14. janv. 08:19 UTC

Tirgus saruna

Bitcoin Rises on Optimism Over Crypto Regulation, Rate Cut Bets -- Market Talk

2026. g. 14. janv. 08:19 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 14. janv. 06:00 UTC

Peļņas

The First Crypto IPO of 2026 Is Coming Soon. It's a Risky Bet. -- Barrons.com

2026. g. 14. janv. 05:30 UTC

Tirgus saruna

Bitcoin Climbs After Decisive Range Breakout, Technical Analysis Shows -- Market Talk

2026. g. 13. janv. 13:09 UTC

Tirgus saruna

Ethereum Could Outperform Bitcoin as Its Prospects Improve -- Market Talk

2026. g. 13. janv. 13:02 UTC

Iegādes, apvienošanās, pārņemšana

Bitcoin Depot Acquires the Assets of Regional Bitcoin ATM Operator, Instant Coin Bank

2026. g. 13. janv. 11:05 UTC

Tirgus saruna

Outflows From Crypto Funds Hold Back Recovery -- Market Talk

2026. g. 13. janv. 08:16 UTC

Tirgus saruna

Bitcoin Edges Higher After U.S. Stocks Rise -- Market Talk

2026. g. 12. janv. 17:51 UTC

Tirgus saruna

Stablecoin Adoption Seen as Gradual Threat to Traditional Fintech -- Market Talk

2026. g. 12. janv. 16:01 UTC

Tirgus saruna

Bitcoin Seen as Alternative Amid Fed Independence Worries -- Market Talk

2026. g. 12. janv. 13:05 UTC

Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: To Continue to Trade on NY Stk Exchange Under the Ticker Symbol BKKT >BKKT

2026. g. 12. janv. 13:05 UTC

Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: Intend to Change Its Corporate Name to Bakkt Inc. >BKKT

2026. g. 12. janv. 13:04 UTC

Iegādes, apvienošanās, pārņemšana

Bakkt Holdings Intercontinental Exchange, Which Beneficially Owns About 31% of Bakkt's Outstanding Class A Common Stk, Has Agreed to Vote Such Shrs in Favor of the Transaction >BKKT

2026. g. 12. janv. 09:38 UTC

Tirgus saruna

Bitcoin Trims Gains as Fed Independence Concerns Mount -- Market Talk

2026. g. 9. janv. 08:00 UTC

Tirgus saruna

Bitcoin Falls Ahead of U.S. Jobs Data -- Market Talk

2026. g. 8. janv. 07:59 UTC

Tirgus saruna

Bitcoin Falls as Traders Take Profits After Recent Gains -- Market Talk

2026. g. 6. janv. 12:26 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 6. janv. 12:26 UTC

Tirgus saruna

Geopolitical Tensions Could Benefit Bitcoin -- Market Talk

Salīdzinājums

Cenas izmaiņa

NeoGenomics Inc Prognoze

Cenas mērķis

By TipRanks

9.46% augšup

Prognoze 12 mēnešiem

Vidējais 14 USD 9.46%

Augstākais 16 USD

Zemākais 12 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi NeoGenomics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam NeoGenomics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

7.7 / 10.27Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par NeoGenomics Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.